FDA "FORCES CEOs TO `BET THE COMPANY'" ON SINGLE LEAD PRODUCT -- CALIFORNIA INSTITUTE; REP. GREENWOOD PREDICTS FDA WILL SUPPORT FINAL REFORM BILL
Executive Summary
"FDA prevents diversification and forces CEOs to `bet the company' on lead products," according to a study based on interviews of California biotech and medical device CEOs prepared by the California Healthcare Institute and Ernst & Young.